MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1215)	5/12/1999 11:01:00 AM
From: Biomaven	Read Replies (1) of 1826

I suspect this ovarian trial news when added to the previous indications of efficacy makes it fairly likely that we will get an approved drug out of MGI-114. A substantial objective response (rather than the uncertain meaning of a decreased marker in the prostate trial) in a patient that has failed first line drugs is always impressive. At this point we still don't know if we are dealing with a niche drug or a blockbuster. However even a niche drug would have a nice impact on MGI's stock price, given they are already above breakeven even after paying for 114's research costs. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next